Alʹmanah Kliničeskoj MedicinyBackground: Dedifferentiated chondrosarcoma (DDCS) is a rare and extremely aggressive variant of mesenchymal bone tumors, with a biphasic structure represented by the classical chondrosarcoma elements, usually of low or intermediate grade, combined with ...
Olga V. Kovaleva +5 more
doaj +1 more source
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies [PDF]
, 2016 Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. While it is true that most lymphoma/leukemia patients can be cured, these regimens are
Ahmadzadeh, V. +2 more
core +1 more source
Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma [PDF]
Journal of Pathology and Translational Medicine, 2016 Background: Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the diagnosis but also for assigning patients to rituximab-containing chemotherapy.
Chang Hwan Choi +8 more
doaj +1 more source
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases [PDF]
, 2017 Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors.
Berno, Tamara +12 more
core +1 more source
Immunopathogenesis of canine chronic ulcerative stomatitis. [PDF]
, 2020 Canine Chronic Ulcerative Stomatitis is a spontaneously occurring inflammatory disease of the oral mucosa. An immune-mediated pathogenesis is suspected though not yet proven.
Anderson, JG +8 more
core +1 more source
A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]
, 2019 The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis +7 more
core +2 more sources
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy
OncoImmunology, 2018 Diminished overall survival rate of non-Hodgkin lymphoma (NHL) patients treated with a combination regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been recently linked to recurrent somatic mutations activating
Beata Pyrzynska +18 more
doaj +1 more source
A Non-Covalent Antibody Complex for the Delivery of anti-cancer drugs [PDF]
, 2019 Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important ...
Grigoletto, Antonella +5 more
core +1 more source
CD20-positive adult T-cell leukemia [PDF]
American Journal of Hematology, 2000 A 67-year-old woman was admitted to our hospital because of lymphadenopathy and lymphocytosis. Monoclonal integration of HTLV-I provirus DNA was detected, and a diagnosis of adult T-cell leukemia (ATL) was made. Flow cytometry revealed that the ATL cells expressed CD20 as well as T-cell-associated antigens, and expression of CD20 mRNA was also ...
M, Yasukawa +5 more
openaire +2 more sources
Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments. [PDF]
, 2012 PurposeAs imaging of the cell surface tetraspan protein epithelial membrane protein-2 (EMP2) expression in malignant tumors may provide important prognostic and predictive diagnostic information, the goal of this study is to determine if antibody ...
Braun, Jonathan +7 more
core +3 more sources